Radiotherapy in Prostate Cancer
Research activity is centered on oligometastatic castration-resistant prostate cancer, with a focus on combining stereotactic body radiotherapy with second-generation antiandrogen treatment in patients with advanced disease.
- Fractionated stereotactic radiotherapy
- Castration-resistant prostate cancer
- Oligometastatic disease
Imaging-based assessment is linked to choline PET/CT and 68Ga-PSMA PET/CT for monitoring radiological progression in metastatic settings.
Androgen Receptor–Targeted Therapy
The sponsor’s therapeutic interest includes second-generation antiandrogens for men with metastatic castration-resistant prostate cancer, particularly in combination with local ablative treatment.
- Second-generation antiandrogen
- Metastatic castration-resistant prostate cancer
- Radiological progression
Clinical activity reflects a strong interest in managing hormone-refractory prostate cancer through integrated systemic and radiation-based approaches.
Molecular Imaging and Disease Monitoring
Research includes the use of advanced PET/CT imaging to characterize disease burden and follow treatment response in prostate cancer.
- Choline PET/CT
- 68Ga-PSMA PET/CT
- Imaging-guided progression assessment
This area supports precise identification of metastatic lesions and treatment-related changes during ongoing oncologic care.
Multicenter Oncology Research
The sponsor is involved in prospective multicenter clinical research across collaborating sites in Spain, with activity concentrated in radiation oncology for advanced genitourinary malignancy.
- Prospective multicenter study
- Radiation oncology
- Genitourinary oncology
Its clinical focus remains tightly aligned with specialized prostate cancer management in a collaborative academic setting.
